

PA-IDC

QUERY CONTROL FORM		RTIS USE ONLY	
Application No. <u>09/880,713</u>	Prepared by <u>NPB</u>	Tracking Number <u>05993597</u>	
Examiner-GAU <u>Ceperley-1641</u>	Date <u>9/14/04</u>	Week Date <u>6/28/04</u>	
	No. of queries <u>2</u>	<u>1PW</u>	

JACKET			
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	<u>s. Sheets/Figs</u>
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

**SPECIFICATION**

a. Page Missing

b. Text Continuity

c. Holes through Data

d. Other Missing Text

e. Illegible Text

f. Duplicate Text

g. Brief Description

h. Sequence Listing

i. Appendix

j. Amendments

k. Other

**CLAIMS**

a. Claim(s) Missing

b. Improper Dependency

c. Duplicate Numbers

d. Incorrect Numbering

e. Index Disagrees

f. Punctuation

g. Amendments

h. Bracketing

i. Missing Text

j. Duplicate Text

k. Other

**MESSAGE**

① Please verify Examiner's Amendment dated 05/11/04: which occurrence/instance of the word "groups" should be deleted on claim 1, line 2. Should both "groups" be deleted? Please verify.

② In drawing sheets dated 04/16/04, there are two(2) FIG. 3A listed. Is this correct? Should the other FIG. 3A be FIG. 3C? Please verify.

*Thompson*

initials *mm*

**RESPONSE**

initials

### Listing of the claims

1. (previously presented) A method for selectively labeling or tagging one or more phosphate groups in a natural or synthetic peptide or protein groups which also contains one or more carboxylic acid groups or esters thereof which method comprises the steps of: *which one to delete?*
  - a. reacting the natural or synthetic peptide or protein with a protective group that is an amine that reacts to protect the one or more phosphate groups therein by forming phosphoramidate bonds and to protect any carboxylic acid groups and esters thereof therein by forming amide bonds;
  - b. treating the protected peptide or protein under conditions which selectively substantially cleave the phosphoramidate bonds, without substantially cleaving the amide bonds to regenerate one or more free phosphate groups in the peptide or protein; and
  - c. reacting the one or more free phosphate groups in the peptide or protein, in which the carboxylic acids groups remain protected, with a label or tag comprising a functional group that reacts with a phosphate group to thereby generate a peptide or protein in which the phosphate groups are selectively labeled or tagged.
2. Canceled
3. (previously presented) The method of claim 1 wherein the label or tag is a solid phase material and the one or more free phosphate groups of the peptide or protein are covalently linked to the solid phase material directly or indirectly through a linker moiety.

Art Unit: 1641

1) An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

2) Claim 1 has been amended as follows:

In claim 1, line two, the word "groups" has been deleted.


3) Authorization for this examiner's amendment was given in a telephone interview with Sally Sullivan on May 11, 2004.

4) An inquiry of a general nature which is not related to the prosecution on the merits should be directed to Technology Center 1600 telephone number (571) 272-1600. The general fax number for the USPTO is (703) 872-9306.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary (Molly) E. Ceperley whose telephone number is (571) 272-0813. The examiner can normally be reached from 8 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le, can be reached on (571) 272-0823.

May 11, 2004

  
Mary (Molly) E. Ceperley  
Primary Examiner  
Art Unit 1641



Inventor: Aebersold  
Filing Date: June 12, 2001  
Attorney Docket No. 39-00

Phosphoangiotensin  
DRV<sub>p</sub>YIH PF




Fig. 3A

